RxDoctor Payments Data

Lindsay Gonzalez, PA

Medical · Rockville, MDNPI 1538481601

Payments from drug & device makers

$5,094in general payments, 2019–2025

Across 230 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$959
  • AstraZeneca$786
  • Novo Nordisk$744
  • Boehringer Ingelheim$337
  • AbbVie$297
  • Johnson & Johnson$296
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,01098%
  • Education$842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,094 in reported general payments places this provider in the 85th percentile of 543 medical providers in Maryland.

See all medical providers in Maryland

Medicare billing

Part B allowed, 2024
$25,933
Medicare patients
107
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$53,462
JardianceEmpagliflozin26$45,543
OzempicSemaglutide30$41,179
Tresiba Flextouch U-200Insulin Degludec21$26,342
EliquisApixaban12$18,263
LinzessLinaclotide14$10,239
Breo ElliptaFluticasone/Vilanterol21$8,418
Atorvastatin Calcium173$1,349
Ezetimibe34$1,287
Diclofenac Sodium19$843
Amlodipine Besylate128$651
Lisinopril99$626
Rosuvastatin Calcium15$513
Metformin Hcl83$434
Losartan Potassium46$411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$959$53,46242 claims
Boehringer IngelheimJardiance$337$45,54326 claims
Novo NordiskOzempic$744$41,17930 claims
PfizerEliquis$87$18,26312 claims
AbbVieLinzess$297$10,23914 claims
GSKBreo Ellipta$64$8,41821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 543 medical providers in Maryland.

Other medical in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →